149 related articles for article (PubMed ID: 2170549)
21. [The values of urine cysteine protein activity in the diagnosis of ovarian cancer].
Xi MR; Peng ZL; Cao ZY
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):85-7, 123. PubMed ID: 8033632
[TBL] [Abstract][Full Text] [Related]
22. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
23. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
24. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
Oishi T; Maruo T; Iwasaki M; Mochizuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
[TBL] [Abstract][Full Text] [Related]
25. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
[TBL] [Abstract][Full Text] [Related]
26. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
27. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas.
Ryuko K; Iwanari O; Kitao M; Moriwaki S
Gynecol Oncol; 1993 May; 49(2):215-24. PubMed ID: 8504990
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
Peters-Engl C; Medl M; Ogris E; Leodolter S
Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
31. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels].
Usui N; Suzuki M; Takada M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun; 44(6):703-9. PubMed ID: 1506732
[TBL] [Abstract][Full Text] [Related]
32. [Applications of tumor markers to the screening of endometrial and ovarian cancers].
Nozawa S; Takamatsu K; Tsukazaki K; Udagawa Y
Nihon Rinsho; 1996 Jun; 54(6):1665-73. PubMed ID: 8691627
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
34. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
35. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
36. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
37. [Study of the mechanism of tumor marker CA125 in serum].
Kiyozuka Y; Noda T; Adachi S; Adachi S; Akada S; Ichijo M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1951-8. PubMed ID: 2592818
[TBL] [Abstract][Full Text] [Related]
38. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
39. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
40. [Clinical evaluation of the tumor marker CA125 in ovarian tumor (a cooperative study among 8 institutions)].
Kato T; Nishimura H; Hamai J; Yamabe T; Nakajima H; Nakano T; Noda K; Teshima K; Suzuki H; Ueda G
Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2338-45. PubMed ID: 3007640
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
